Empirical Finance’s Enanta Pharmaceuticals ENTA Stock Holding History

Empirical Finance’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-123	Closed	-$5K	–	239
2016 Q4	$5K	Buy	+123	New	+$3.53K	﹤0.01%	528

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

MCM

Matarin Capital Management New York $409M AUM 33.03% 1-Year Est. Return

Empirical Finance's ENTA Position: Q1 2017 in Review

Empirical Finance sold out of Enanta Pharmaceuticals (ENTA) in Q1 2017, closing a stake of 123 shares — an estimated $5K sold.

Empirical Finance first reported a position in ENTA in Q4 2016 and held it in 1 quarter. The position peaked at $5K in Q4 2016. 126 funds tracked by Wall St. Rank hold ENTA as of Q1 2017.

Empirical Finance reported no remaining Enanta Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Empirical Finance sold 123 Enanta Pharmaceuticals shares in Q1 2017, an estimated $5K.
Empirical Finance first reported a position in Enanta Pharmaceuticals in Q4 2016 and held it in 1 quarter.
Empirical Finance's Enanta Pharmaceuticals position peaked at $5K in Q4 2016.
126 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2017.

Based on Empirical Finance's 13F filing for Q1 2017, filed 11 May 2017.